Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor

Wenxian Wang; Qian Wang; Chunwei Xu; Ziming Li; Zhengbo Song; Yongchang Zhang; Xiuyu Cai; Shirong Zhang; Bin Lian; Wen Li; Anwen Liu; Ping Zhan; Hongbing Liu; Tangfeng Lv; Liyun Miao; Lingfeng Min; Yu Chen; Jingping Yuan; Feng Wang; Zhansheng Jiang; Gen Lin; Xingxiang Pu; Chuangzhou Rao; Dongqing Lv; Zongyang Yu; Xiaoyan Li; Chuanhao Tang; Chengzhi Zhou; Congying Xie; Junping Zhang; Hui Guo; Qian Chu; Rui Meng; Jingxun Wu; Rui Zhang; Liping Wang; Youcai Zhu; Xiao Hu; Yanru Xie; Xinqing Lin; Jing Cai; Fen Lan; Huijing Feng; Lin Wang; Wang Yao; Xuefei Shi; Jianhui Huang; Huafei Chen; Yinbin Zhang; Pingli Sun; Bing Wan; Fei Pang; Zanmei Xu; Kai Wang; Yuanli Xia; Mingxiang Ye; Dong Wang; Qing Wei; Shuitu Feng; Jianya Zhou; Jiexia Zhang; Donglai Lv; Wenbin Gao; Jing Kang; Genhua Yu; Xianbin Liang; Chengtao Yu; Lin Shi; Nong Yang; Lin Wu; Zhuan Hong; Wei Hong; Meiyu Fang; Yiping Zhang; Yuanzhi Lu; Guansong Wang; Shenglin Ma; Lu Si; Wenfeng Fang; Yong Song

doi:10.1111/1759-7714.14693

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor

Wenxian Wang
, Qian Wang
, Chunwei Xu
, Ziming Li
, Zhengbo Song
, Yongchang Zhang
, Xiuyu Cai
, Shirong Zhang
, Bin Lian
, Wen Li
, Anwen Liu
, Ping Zhan
, Hongbing Liu
, Tangfeng Lv
, Liyun Miao
, Lingfeng Min
, Yu Chen
, Jingping Yuan
, Feng Wang
, Zhansheng Jiang

Gen Lin, Xingxiang Pu, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Congying Xie, Junping Zhang, Hui Guo, Qian Chu, Rui Meng, Jingxun Wu, Rui Zhang, Liping Wang, Youcai Zhu, Xiao Hu, Yanru Xie, Xinqing Lin, Jing Cai, Fen Lan, Huijing Feng, Lin Wang, Wang Yao, Xuefei Shi, Jianhui Huang, Huafei Chen, Yinbin Zhang, Pingli Sun, Bing Wan, Fei Pang, Zanmei Xu, Kai Wang, Yuanli Xia, Mingxiang Ye, Dong Wang, Qing Wei, Shuitu Feng, Jianya Zhou, Jiexia Zhang, Donglai Lv, Wenbin Gao, Jing Kang, Genhua Yu, Xianbin Liang, Chengtao Yu, Lin Shi, Nong Yang, Lin Wu, Zhuan Hong, Wei Hong, Meiyu Fang, Yiping Zhang, Yuanzhi Lu, Guansong Wang, Shenglin Ma, Lu Si, Wenfeng Fang, Yong Song

Chinese Academy of Sciences
Affiliated Hospital of Nanjing University of Chinese Medicine
Nanjing University
Shanghai Jiao Tong University
Central South University
Sun Yat-Sen University Cancer Center
Zhejiang University School of Medicine
Peking University
The Second Affiliated Hospital of Zhejiang University School of Medicine
Nanchang University
Yangzhou University
Fujian Medical University
Renmin Hospital of Wuhan University
Tianjin Medical University
University of Chinese Academy of Sciences
Wenzhou Medical University
Capital Medical University
The First Affiliated Hospital of Guanzhou Medical University
Shanxi Bethune Hospital
The First Affiliated Hospital of Xi’an Jiaotong University
Huazhong University of Science and Technology
Xiamen University
China Medical University
Baotou Cancer Hospital
Jiaxing University
Lishui Central Hospital
Sun Yat-Sen University
Zhejiang University
Xi'an Jiaotong University
Jilin University
The Affiliated Jiangning Hospital of Nanjing Medical University
Shanghai OrigiMed Co. Ltd
AstraZeneca
Xiamen Haicang Hospital
Zhejiang University School of Medicine
The 901 Hospital of Joint Logistics Support Force of People Liberation Army
Shenzhen University
Guangdong Academy of Medical Sciences
Zhebei Mingzhou Hospital
The Third People's Hospital of Zhengzhou
Collaborative Innovation Center of Jiangsu Province of Cancer Prevention and Treatment of Chinese Medicine
Fudan University
Jiangsu Institute of Cancer Institute & Hospital
The First Affiliated Hospital of Jinan University
Army Medical University

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in clinical practice, the increasing checkpoint inhibitor pneumonia (CIP) will be a challenge to clinicians. To guide the diagnosis and treatment of CIP, we conducted in-depth discussions based on the latest evidence, forming a consensus among Chinese experts on the multidisciplinary management of CIP.

Original language	English
Pages (from-to)	3420-3430
Number of pages	11
Journal	Thoracic Cancer
Volume	13
Issue number	23
DOIs	https://doi.org/10.1111/1759-7714.14693
State	Published - Dec 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Chinese experts consensus
checkpoint inhibitor pneumonitis
immune checkpoint inhibitor-related adverse effects

Access to Document

10.1111/1759-7714.14693

Cite this

Wang, W., Wang, Q., Xu, C., Li, Z., Song, Z., Zhang, Y., Cai, X., Zhang, S., Lian, B., Li, W., Liu, A., Zhan, P., Liu, H., Lv, T., Miao, L., Min, L., Chen, Y., Yuan, J., Wang, F., ... Song, Y. (2022). Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor. Thoracic Cancer, 13(23), 3420-3430. https://doi.org/10.1111/1759-7714.14693

@article{4652a5b3d82d4570a6850a9942a1c51e,

title = "Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor",

abstract = "Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in clinical practice, the increasing checkpoint inhibitor pneumonia (CIP) will be a challenge to clinicians. To guide the diagnosis and treatment of CIP, we conducted in-depth discussions based on the latest evidence, forming a consensus among Chinese experts on the multidisciplinary management of CIP.",

keywords = "Chinese experts consensus, checkpoint inhibitor pneumonitis, immune checkpoint inhibitor-related adverse effects",

author = "Wenxian Wang and Qian Wang and Chunwei Xu and Ziming Li and Zhengbo Song and Yongchang Zhang and Xiuyu Cai and Shirong Zhang and Bin Lian and Wen Li and Anwen Liu and Ping Zhan and Hongbing Liu and Tangfeng Lv and Liyun Miao and Lingfeng Min and Yu Chen and Jingping Yuan and Feng Wang and Zhansheng Jiang and Gen Lin and Xingxiang Pu and Chuangzhou Rao and Dongqing Lv and Zongyang Yu and Xiaoyan Li and Chuanhao Tang and Chengzhi Zhou and Congying Xie and Junping Zhang and Hui Guo and Qian Chu and Rui Meng and Jingxun Wu and Rui Zhang and Liping Wang and Youcai Zhu and Xiao Hu and Yanru Xie and Xinqing Lin and Jing Cai and Fen Lan and Huijing Feng and Lin Wang and Wang Yao and Xuefei Shi and Jianhui Huang and Huafei Chen and Yinbin Zhang and Pingli Sun and Bing Wan and Fei Pang and Zanmei Xu and Kai Wang and Yuanli Xia and Mingxiang Ye and Dong Wang and Qing Wei and Shuitu Feng and Jianya Zhou and Jiexia Zhang and Donglai Lv and Wenbin Gao and Jing Kang and Genhua Yu and Xianbin Liang and Chengtao Yu and Lin Shi and Nong Yang and Lin Wu and Zhuan Hong and Wei Hong and Meiyu Fang and Yiping Zhang and Yuanzhi Lu and Guansong Wang and Shenglin Ma and Lu Si and Wenfeng Fang and Yong Song",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley \& Sons Australia, Ltd.",

year = "2022",

month = dec,

doi = "10.1111/1759-7714.14693",

language = "英语",

volume = "13",

pages = "3420--3430",

journal = "Thoracic Cancer",

issn = "1759-7706",

publisher = "John Wiley and Sons Inc",

number = "23",

}

Wang, W, Wang, Q, Xu, C, Li, Z, Song, Z, Zhang, Y, Cai, X, Zhang, S, Lian, B, Li, W, Liu, A, Zhan, P, Liu, H, Lv, T, Miao, L, Min, L, Chen, Y, Yuan, J, Wang, F, Jiang, Z, Lin, G, Pu, X, Rao, C, Lv, D, Yu, Z, Li, X, Tang, C, Zhou, C, Xie, C, Zhang, J, Guo, H, Chu, Q, Meng, R, Wu, J, Zhang, R, Wang, L, Zhu, Y, Hu, X, Xie, Y, Lin, X, Cai, J, Lan, F, Feng, H, Wang, L, Yao, W, Shi, X, Huang, J, Chen, H, Zhang, Y, Sun, P, Wan, B, Pang, F, Xu, Z, Wang, K, Xia, Y, Ye, M, Wang, D, Wei, Q, Feng, S, Zhou, J, Zhang, J, Lv, D, Gao, W, Kang, J, Yu, G, Liang, X, Yu, C, Shi, L, Yang, N, Wu, L, Hong, Z, Hong, W, Fang, M, Zhang, Y, Lu, Y, Wang, G, Ma, S, Si, L, Fang, W & Song, Y 2022, 'Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor', Thoracic Cancer, vol. 13, no. 23, pp. 3420-3430. https://doi.org/10.1111/1759-7714.14693

TY - JOUR

T1 - Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor

AU - Wang, Wenxian

AU - Wang, Qian

AU - Xu, Chunwei

AU - Li, Ziming

AU - Song, Zhengbo

AU - Zhang, Yongchang

AU - Cai, Xiuyu

AU - Zhang, Shirong

AU - Lian, Bin

AU - Li, Wen

AU - Liu, Anwen

AU - Zhan, Ping

AU - Liu, Hongbing

AU - Lv, Tangfeng

AU - Miao, Liyun

AU - Min, Lingfeng

AU - Chen, Yu

AU - Yuan, Jingping

AU - Wang, Feng

AU - Jiang, Zhansheng

AU - Lin, Gen

AU - Pu, Xingxiang

AU - Rao, Chuangzhou

AU - Lv, Dongqing

AU - Yu, Zongyang

AU - Li, Xiaoyan

AU - Tang, Chuanhao

AU - Zhou, Chengzhi

AU - Xie, Congying

AU - Zhang, Junping

AU - Guo, Hui

AU - Chu, Qian

AU - Meng, Rui

AU - Wu, Jingxun

AU - Zhang, Rui

AU - Wang, Liping

AU - Zhu, Youcai

AU - Hu, Xiao

AU - Xie, Yanru

AU - Lin, Xinqing

AU - Cai, Jing

AU - Lan, Fen

AU - Feng, Huijing

AU - Wang, Lin

AU - Yao, Wang

AU - Shi, Xuefei

AU - Huang, Jianhui

AU - Chen, Huafei

AU - Zhang, Yinbin

AU - Sun, Pingli

AU - Wan, Bing

AU - Pang, Fei

AU - Xu, Zanmei

AU - Wang, Kai

AU - Xia, Yuanli

AU - Ye, Mingxiang

AU - Wang, Dong

AU - Wei, Qing

AU - Feng, Shuitu

AU - Zhou, Jianya

AU - Zhang, Jiexia

AU - Lv, Donglai

AU - Gao, Wenbin

AU - Kang, Jing

AU - Yu, Genhua

AU - Liang, Xianbin

AU - Yu, Chengtao

AU - Shi, Lin

AU - Yang, Nong

AU - Wu, Lin

AU - Hong, Zhuan

AU - Hong, Wei

AU - Fang, Meiyu

AU - Zhang, Yiping

AU - Lu, Yuanzhi

AU - Wang, Guansong

AU - Ma, Shenglin

AU - Si, Lu

AU - Fang, Wenfeng

AU - Song, Yong

PY - 2022/12

Y1 - 2022/12

N2 - Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in clinical practice, the increasing checkpoint inhibitor pneumonia (CIP) will be a challenge to clinicians. To guide the diagnosis and treatment of CIP, we conducted in-depth discussions based on the latest evidence, forming a consensus among Chinese experts on the multidisciplinary management of CIP.

AB - Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in clinical practice, the increasing checkpoint inhibitor pneumonia (CIP) will be a challenge to clinicians. To guide the diagnosis and treatment of CIP, we conducted in-depth discussions based on the latest evidence, forming a consensus among Chinese experts on the multidisciplinary management of CIP.

KW - Chinese experts consensus

KW - checkpoint inhibitor pneumonitis

KW - immune checkpoint inhibitor-related adverse effects

UR - https://www.scopus.com/pages/publications/85140206493

U2 - 10.1111/1759-7714.14693

DO - 10.1111/1759-7714.14693

M3 - 文章

C2 - 36268845

AN - SCOPUS:85140206493

SN - 1759-7706

VL - 13

SP - 3420

EP - 3430

JO - Thoracic Cancer

JF - Thoracic Cancer

IS - 23

ER -

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this